Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Arrowhead Pharmaceuticals

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million.

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share.

Royalty Pharma Declares Second Quarter 2024 Dividend

ACADIA Pharma

Moderna

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.

3 Pharma Stocks to Sell in April Before They Crash & Burn

Samsara

New Mountain Finance

The Forbes 400 is a list of America's 400 wealthiest people. Right now, to get on the coveted list, one's net worth has to be at least $2.9 billion.

Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You've Never Heard Of)

Alliance Resource Partners

SPDR Gold Trust

​Today we dive deeper than the headlines ​to uncover overlooked stocks​. In the ​artificial intelligence (AI​) market of ​2024, tech giants dominated the first quarter.

April's Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio

AMN Healthcare Services

Bristol-Myers

CVS Health

Patterson Companies

Semler Scientific

Voyager Therapeutics

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET.

Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference

While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Alibaba

Schlumberger

SLB expects strong growth in 2024. Alibaba stock is dirt cheap, and the company plans major buybacks over the next few years.

Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts. “Royalty Pharma delivered outstanding results in 2023,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. “We reported another year of strong growth in royalty receipts and deployed substantial capital in value-enhancing transactions, including our strongest year ever for synthetic royalty transactions. Furthermore, a number of positive clinical and regulatory milestones strengthened the outlook for our diversified royalty portfolio. Based on the strong fundamental tailwinds underpinning our business, our strong balance sheet and robust deal pipeline, I am confident we are in an excellent position to fund life sciences innovation and deliver attractive, long-term compounding growth.”

Royalty Pharma Reports Q4 and Full Year 2023 Results

Cytokinetics

Denali Therapeutics

The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.

3 Biotech Stocks to Buy for the Next Bull Run: February 2024

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

Royalty Pharma is a unique pharmaceutical company that diversifies investments in market-leading or late-stage development therapies. RPRX has a dominant position in the pharmaceutical royalty market and shares in the profits of successful pharmaceutical development projects. The outlook is getting better driven by strong industry tailwinds like new technologies in developing drugs and treatments, and biopharma turning to royalty deals as an alternative financing strategy.

Royalty Pharma: One Of The Best Names In Pharmaceuticals

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend.

Royalty Pharma Announces Dividend Increase

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

Blackstone Group

Investors looking for stocks in the Financial - Miscellaneous Services sector might want to consider either Royalty Pharma (RPRX) or Blackstone Inc. (BX). But which of these two companies is the best option for those looking for undervalued stocks?

RPRX or BX: Which Is the Better Value Stock Right Now?

Teva Pharmaceutical

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): In a joint press release announcing the financing agreement: Richard Francis, President and CEO of Teva said: “Since launching Teva's Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to both continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses. We are excited to collaborate with Royalty Pharma, a major funder of innovation wi.

MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)

NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accelerate the clinical research program for Teva's olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile.

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva's olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypical.

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma PLC (NASDAQ:RPRX ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Stephen Scala - TD Cowen Andrew Baum - Citigroup Michael DiFiore - Evercore ISI Chris Shibutani - Goldman Sachs Group Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call.

Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) --  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance for Adjusted Cash Receipts( 1) (a non-GAAP financial measure).

News for Royalty Pharma Stock (RPRX)